Ruxolitinib-Enhanced Haplo HCT for Children and Young Adults With Sickle Cell Disease

Clinical trial NCT07252050 · RECRUITING

Trial details

NCT number: NCT07252050
Sponsor: Arkansas Children's Hospital Research Institute
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Sickle Cell Disease Hematopoetic Stem Cell Transplant Haploidentical Hematopoietic Stem Cell Transplant Haploidentical Stem Cell Transplantation Graft Failure

Start date: 2026-06-08
Primary completion: 2028-11-19
Enrollment: 24

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.